The Supreme Court is preparing to help Bayer escape liability for causing cancer in tens of thousands of people who used Roundup. The company’s proposed $7.25 billion buyout of those claims—a settlement that would extinguish the rights of people who sprayed the weedkiller on farms, lawns, and community gardens—is the preemption play. If the Court’s six-justice corporate-docket majority delivers the outcome its oral-argument signals indicated, the settlement will be the only money the victims ever see. Bayer pays out now because the federal regulator’s silence on the label is about to become permanent law, and the settlement clears the liability ledger before the Court rules.
John Durnell sprayed Roundup on a St. Louis community garden for more than twenty years and then developed non-Hodgkin lymphoma. He sued in Missouri state court, alleging that Monsanto—bought by Bayer in 2018—failed to warn that its flagship product could cause cancer. Bayer answered that the lawsuit must be dismissed because federal law preempts any state‑law duty to add a cancer warning to the label. Under the Federal Insecticide, Fungicide, and Rodenticide Act, a manufacturer must obtain EPA approval of every pesticide label, and a state may not impose a requirement “in addition to or different from” the federally approved label. The EPA has repeatedly decided, most recently in a 2019 interim registration review, that glyphosate is not likely to be carcinogenic when used as directed. Bayer’s logic is straightforward: state juries cannot hold the company liable for failing to include a warning the EPA itself says is unnecessary. A working-bar attorney aligned with the company would recognize this as the strongest card in the deck—a preemption argument with a textual foothold and a doctrinal chassis that a conservative Court has shown a strong appetite for in cases from PLIVA v. Mensing to Kisor v. Wilkie.
The steel‑man stops there. The audit starts with what the EPA’s regulatory posture actually means. FIFRA’s preemption clause prevents a state from requiring a statement that contradicts the EPA‑approved label. But the EPA does not prohibit a manufacturer from voluntarily adding a warning. The agency’s registration process establishes a floor; a company that knows its product is carcinogenic—or that the World Health Organization’s International Agency for Research on Cancer classified glyphosate as “probably carcinogenic to humans” in 2015—can and should add a caution to the label without waiting for an EPA mandate. Bayer has never done so. When Durnell’s lawyers argue that the company had a state‑law duty to supplement the federal label with a cancer warning, they are not asking a Missouri jury to contradict the EPA; they are asking the jury to find that a manufacturer possessed information that made the federally approved label misleading by omission. That is not a labeling requirement that is “in addition to or different from” the EPA’s own; it is a gap‑filling duty that every state product‑liability regime has recognized for decades. The Supreme Court itself endorsed that framework in Wyeth v. Levine, where it held that a state failure‑to‑warn claim against a branded drug manufacturer was not preempted because the drug company could have added a stronger warning to the FDA‑approved label without the agency’s permission—and the same regulatory structure governs pesticide labeling.
Yet the Roberts Court has never applied Wyeth’s reasoning to a pesticide case. Instead, it has built a parallel preemption doctrine that treats industry‑favored agency silence as law, erasing the distinction between what a federal regulator forbids and what a federal regulator simply declines to require. The EPA did not prohibit a cancer warning; it merely concluded that the evidence it chose to review did not justify compelling one. When a federal agency’s no‑action is converted by the Court into a shield that destroys every parallel state remedy, the company that caused the harm keeps the money, and the injured person bears the loss alone. That is not preemption grounded in conflict; it is corporate immunity dressed as statutory interpretation. The conservative legal movement’s asymmetric deployment of preemption—aggressively expanding it for business defendants while contracting it for individuals in the same Term—fits a long‑documented pattern. The same majority that insists on strict textualism when the text favors a corporate defendant is comfortable reading a regulatory gap as a congressional command. The arc of the Court’s work is not hidden: from Geier v. American Honda to Mutual Pharmaceutical Co. v. Bartlett, the Federalist Society litigation pipeline has fed the Court cases engineered to produce an immunity regime for regulated industries, and the six‑member business‑docket bloc has delivered.
Now the settlement comes into view. Bayer proposed to pay as much as $7.25 billion over up to twenty‑one years into a fund that would resolve most pending Roundup suits. The per‑claimant numbers betray the scale of the haircut: an agricultural worker with aggressive non‑Hodgkin lymphoma diagnosed before age sixty would get an average of $165,000; if the same person were diagnosed at seventy‑eight or older, the average falls to $10,000. Those are not compensatory sums; they are nuisance‑value payouts structured to disappear the litigation before the Supreme Court can tell the victims that their state‑court claims are worth nothing. An objecting attorney, Ashley Keller, has filed to remove the case to federal court and fight the June 4 opt‑out deadline, recognizing that the settlement’s closure is a preemption play. The settlement’s timeline—opt‑out deadline in early June, a July 9 state‑court hearing—is running the clock against the Court’s expected June opinion. The settlement excludes John Durnell, the named plaintiff whose case is pending at the Supreme Court, because if the Court rules against him, Bayer’s future liability drops to near zero, and the $7.25 billion looks like a preemptive discount on a liability stream the Court is about to terminate.
The science fight is genuine. The World Health Organization classifies glyphosate as probably carcinogenic; the EPA disagrees. The epidemiological record is contested. But the preemption doctrine does not turn on the science. It turns on the legal lock. If the manufacturer wins Durnell, the federal label immunizes it from liability regardless of what the epidemiological record shows in five years. Converting the EPA’s silence into a shield is legalizing toxic silence. What an honest doctrinal application would require is a mechanism that forces the federal regulator to maintain a current, adversarial review of the chemical’s safety data when the epidemiological record shifts, coupled with a statutory pathway for state tort plaintiffs to petition for label updates. Under the current implied‑preemption architecture, the manufacturer holds the federal label and the state tort is foreclosed; the regulator operates on a decades‑old risk assessment; and the injured party is left with a label that the manufacturer drafted and the regulator approved without addressing the IARC finding.
The Durnell opinion will arrive before the July 9 Missouri hearing. If the Court grants Bayer the preemption defense, the failure‑to‑warn tort for agricultural chemicals is dead. The $7.25 billion settlement is the final price for the liability shield the Court has built. The cancer victims are paid out—an average of $165,000 for those diagnosed young, $10,000 for those diagnosed after seventy‑eight. The regulatory silence is preserved. The ledger clears. That is the structural reality the opinion will write into law when it drops at the end of June. When the federal judiciary tells a multinational that it can buy off an entire generation of cancer claims for ten thousand dollars a life, the Court is not refereeing a legal dispute; it is setting the price of human life in a corporate economy.